Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
About the Editors xvii
List of Contributors xix
Series Preface xxv
Preface xxvii
1 Continuous Manufacturing: Definitions and Engineering Principles 1Johannes Khinast and Massimo Bresciani
1.1 Introduction 1
1.1.1 Definition of Continuous Manufacturing 1
1.1.2 Continuous Manufacturing in the Pharmaceutical Industry 2
1.1.3 Our View of Continuous Manufacturing 3
1.1.4 Regulatory Environment 8
1.2 Advantages of Continuous Manufacturing 8
1.2.1 Flexibility 8
1.2.2 Effect on the Supply Chain 8
1.2.3 Agility and Reduced Scale-up Efforts 9
1.2.4 Real-Time Quality Assurance and Better Engineered Systems 9
1.2.5 Decentralized Manufacturing 10
1.2.6 Individualized Manufacturing 10
1.2.7 Reduced Floor Space and Investment Costs 10
1.2.8 More Efficient Chemistries 10
1.2.9 Societal Benefits 11
1.3 Engineering Principles of Continuous Manufacturing 11
1.3.1 Pharmaceutical Unit Operations 11
1.3.2 Fundamentals of Process Modeling 15
1.3.3 Balance Equations for Mass, Species, Energy and Momentum 16
1.3.4 Residence Time Distribution 20
1.3.5 Classical Reactor Types as a Basis for Process Understanding 21
1.3.6 Process Control, Modeling and PAT 24
1.3.7 Scale-Up 26
1.3.8 Dimensioning 27
1.4 Conclusion 28
References 30
2 Process Simulation and Control for Continuous Pharmaceutical Manufacturing of Solid Drug Products 33Marianthi Ierapetritou, M. Sebastian Escotet-Espinoza and Ravendra Singh
2.1 Introduction 33
2.1.1 Scope and Motivation 33
2.1.2 Process Simulation 34
2.1.3 Process Control 36
2.2 Pharmaceutical Solid Dosage Manufacturing Processes 38
2.2.1 Overview 38
2.2.2 Continuous Manufacturing Processes 38
2.2.3 Continuous Process Equipment 39
2.3 Mathematical Modeling Approaches 44
2.3.1 First Principle "Mechanistic" Models 44
2.3.2 Multi-dimensional Population Balance Models 44
2.3.3 Engineering or Phenomenological Models 46
2.3.4 Empirical and Reduced Order Models 47
2.4 Unit Operations Models 48
2.4.1 Feeders 48
2.4.2 Blenders (Mixers) 56
2.4.3 Tablet Press 63
2.4.4 Roller Compactor 67
2.4.5 Wet Granulation 71
2.4.6 Drying 75
2.4.7 Milling/Co-milling 76
2.4.8 Flowsheet Modeling 77
2.5 Process Control of Continuous Solid-based Drug Manufacturing 81
2.5.1 Process Control Basics 83
2.5.2 Control Design of Continuous Pharmaceutical Manufacturing Process 84
2.6 Summary 93
Acknowledgments 94
References 94
3 Regulatory and Quality Considerations for Continuous Manufacturing 107Gretchen Allison, Yanxi Tan Cain, Charles Cooney, Tom Garcia, Tara Gooen Bizjak, Oyvind Holte, Nirdosh Jagota, Bekki Komas, Evdokia Korakianiti, Dora Kourti, Rapti Madurawe, Elaine Morefield, Frank Montgomery, Moheb Nasr, William Randolph, Jean-Louis Robert, Dave Rudd and Diane Zezza
3.1 Introduction 108
3.2 Current Regulatory Environment 108
3.3 Existing Relevant Regulations, Guidelines, and Standards Supporting Continuous Manufacturing 108
3.3.1 ICH Guidelines 108
3.3.2 United States Food and Drug Administration Guidances 109
3.3.3 US FDA Guidance on Process Validation 109
3.3.4 American Society for Testing and Materials Standards 109
3.3.5 European Union Guidelines 110
3.4 Regulatory Considerations 110
3.4.1 Development Considerations for Continuous Manufacturing 111
3.4.2 Special Considerations for Control Strategy in Continuous Manufacturing 112
3.4.3 Stability Considerations for Continuous Manufacturing 114
3.5 Quality/GMP Considerations 115
3.5.1 Pharmaceutical Quality Systems 115
3.5.2 Batch Release 115
3.5.3 Startup and Shutdown Procedures 116
3.5.4 State of Control: Product Collection and In-process Sampling 117
3.5.5 Process Validation and CPV 117
3.5.6 Material Traceability in Continuous Manufacturing 119
3.5.7 Handling of Raw Material and In-process Material 119
3.5.8 Detection and Treatment for Non-conformity 119
3.5.9 Personnel Procedures and Training 120
3.5.10 Material Carry-over 120
3.5.11 Material Diversion 120
3.5.12 Production Floor Product Monitoring 121
3.5.13 Raw Material Variability 121
3.5.14 Cleaning Validation 121
3.5.15 Equipment Failure 122
3.6 Quality Considerations for Bridging Existing Batch Manufacturing to Continuous Manufacturing 122
3.6.1 Physicochemical Equivalence Considerations 123
3.6.2 Bioequivalence Considerations 123
3.7 Glossary and Definitions 123
3.7.1 Batch Definition 123
3.7.2 21cfr 210.3 124
3.7.3 Cfr 211 124
3.7.4 Ich Q 7 124
3.7.5 Ich Q 10 124
3.8 General Regulatory References 124
3.8.1 cGMP Guidance 125
4 Continuous Manufacturing of Active Pharmaceutical Ingredients via Flow Technology 127Svetlana Borukhova and Volker Hessel
4.1 Introduction 127
4.2 Micro Flow Technology 128
4.2.1 Micromixing 129
4.2.2 Flow Reactors 130
4.2.3 Reaction Activation Tools 130
4.2.4 Downstream Processing 139
4.2.5 Process Analytical Technology and Automation 142
4.3 Multi-step Synthesis of Active Pharmaceutical Ingredients in Micro Flow 150
4.3.1 Aliskiren 151
4.3.2 Artemisinin 151
4.3.3 Ibuprofen 153
4.3.4 Gleevec 154
4.3.5 Nabumetone 155
4.3.6 Quinolone Derivative as a Potent 5HT 1B Antagonist 155
4.3.7 Rufinamide 155
4.3.8 Thioquinazolinone 156
4.4 Larger-scale Syntheses 156
4.4.1 Hydroxypyrrolotriazine (Bristol-Myers-Squibb) 156
4.4.2 2,2-Dimethylchromenes (Bristol-Myers-Squibb) 156
4.4.3 Fused-Bycyclic Isoxazolidines (Eli Lilly and Company) 158
4.4.4 7-Ethyltryptophol on the Way to Etodolac 158
4.4.5 6-Hydroxybuspirone (Bristol-Myers-Squibb) 159
4.5 Current Industrial Applications 160
4.6 Conclusion and Outlook 161
References 162
5 Continuous Crystallisation 169Cameron Brown, Thomas McGlone and Alastair Florence
5.1 Introduction 169
5.2 Principles of Crystallisation 173
5.2.1 Supersaturation 173
5.2.2 Nucleation and Growth 176
5.2.3 Conservation Equations 180
5.3 Crystallisation Process Development 180
5.4 Continuous Crystallisers and Applications 185
5.4.1 Mixed Suspension Mixed Product Removal 186
5.4.2 MSMPR Cascade 193
5.4.3 Plug Flow Reactors 198
5.4.4 Impinging Jet 206
5.4.5 Microfluidics 207
5.5 Process Monitoring, Analysis and Control 207
5.5.1 Process Monitoring and Analysis 207
5.5.2 Crystallisation Control Strategies 211
5.6 Particle Characterisation 213
5.7 Concluding Remarks 215
References 217
6 Continuous Fermentation for Biopharmaceuticals? 227L. Mears, H. Feldman, F.C. Falco, C. Bach, M. Wu, A. Nørregaard and K.V. Gernaey
6.1 Introduction 227
6.1.1 Definition of Fermentation 227
6.1.2 Production of Biopharmaceuticals 228
6.1.3 Structure of Chapter 228
6.2 Operation of Fermentation Systems 229
6.2.1 Comparison of Different Cultivation Systems 229
6.2.2 Monitoring of Continuous Fermentation Processes 232
6.2.3 Control of Continuous Fermentation Processes 234
6.3 Continuous Fermentation Examples 238
6.3.1 Continuous Ethanol Fermentation 238
6.3.2 Continuous Lactic Acid Fermentation 239
6.3.3 Single Cell Protein Production 240
6.4 Discussion 241
6.5 Conclusions 243
References 244
7 Integrated Continuous Manufacturing of Biopharmaceuticals 247Alois Jungbauer and Nikolaus Hammerschmidt
7.1 Background 247
7.1.1 Current Status of Manufacturing of Biopharmaceuticals 247
7.1.2 Challenges to Developing Continuous Processes 249
7.1.3 Rationale for Continuous Biomanufacturing 250
7.2 Continuous Upstream Processing 251
7.2.1 Cell Lines and Cell Line Stability 251
7.2.2 Perfusion Reactor 252
7.2.3 Cell Retention Devices 252
7.2.4 Chemostat and Turbidostat 254
7.2.5 Overview of Products Produced by Continuous Upstream Processing 254
7.3 Continuous Downstream Processing 257
7.3.1 Overview of Unit Operations 257
7.3.2 Continuous Centrifuges 257
7.3.4 Continuous Chromatography 260
7.3.5 Continuous Precipitation 263
7.3.6 Continuous Formulation 266
7.4 Process Integration and Single Use Technology 266
7.4.1 Disposable Bioreactors 268
7.4.2 Disposable Unit Operations in Downstream Processing 268
7.4.3 Full Process Train 270
7.5 Process Monitoring and Control 270
7.6 Process Economics of Continuous Manufacturing 274
7.7 Conclusions 275
Acknowledgments 276
References 276
8 Twin-screw Granulation Process Development: Present Approaches, Understanding and Needs 283A. Kumar, K.V. Gernaey, I. Nopens and T. De Beer
8.1 Introduction 283
8.2 Continuous Wet-granulation using a TSG 284
8.3 Components of High Shear Wet Granulation in a TSG 287
8.4 Material Transport and Mixing in a TSG 287
8.4.1 Granulation Time in a TSG 288
8.4.2 Mixing in a TSG 291
8.5 Granule Size Evolution During Twin-screw Granulation 294
8.5.1 Granule Size and Shape Dynamics in a TSG 295
8.5.2 Link Between RTD, Liquid Distribution and GSD in a TSG 295
8.6 Model-based Analysis of Twin-screw Granulation 298
8.6.1 Modelling RTD in a TSG 298
8.6.2 Tracking GSD in a TSG using PBM 300
8.7 Towards Generic Twin-screw Granulation Knowledge 302
8.7.1 Regime Map Approach 303
8.7.2 Particle-scale Simulation using DEM 305
8.8 Strengths and Limitations of the Current Approaches in TSG Studies 307
8.9 Glossary 308
References 309
9 Continuous Line Roller Compaction 313Ossi Korhonen
9.1 Roller Compaction 313
9.2 Main Components of a Roller Compactor 313
9.3 Theory of Powder Densification in Roller Compaction 315
9.4 Johanson Model 317
9.5 Modified Johanson Model 319
9.6 Experimental Observations of Pressure Distribution from Instrumented Roller Compactors 322
9.7 Off-line Characterization of Ribbon Quality 324
9.8 In-line Monitoring of Roller Compaction Process 326
9.9 Formulative Aspects of Roller Compaction 328
9.10 Roller Compaction as a Unit Operation in Continuous Manufacturing 330
9.11 Process Control of Continuous Roller Compaction 332
9.12 Conclusions 333
References 334
10 Continuous Melt Extrusion and Direct Pelletization 337Stephan Laske, Theresa Hörmann, Andreas Witschnigg, Gerold Koscher, Patrick Wahl, Wen Kai Hsiao and Johannes Khinast
10.1 Introduction 337
10.2 The Extruder 338
10.3 Feeding 341
10.3.1 Solid Feeding 341
10.3.2 LIW Screw Feeders 342
10.4 Twin-screw Extrusion 345
10.4.1 Counter-rotating Twin-screw Extruder 346
10.4.2 Co-rotating Twin-screw Extruder 347
10.5 Operation Point 347
10.6 Downstream Processing 349
10.6.1 Direct Shaping of Final Product 350
10.6.2 Intermediate Products 352
10.7 Continuous Manufacturing with HME 356
10.7.1 Process Understanding 356
10.7.2 Control Strategy 356
10.7.3 State of Control 357
10.7.4 Diversion of Material 357
10.8 PAT for HME 360
10.8.1 Near-infrared Spectroscopy 360
10.8.2 Raman Spectroscopy 360
10.8.3 Chemical Imaging 361
10.8.4 Particle Size Analysis 361
10.8.5 Optical Coherence Tomography 361
10.8.6 Data Processing 362
10.9 Process Integration into Computerized Systems 362
10.9.1 IT Structure of Supervisory Control Systems 364
10.9.2 Real-time Release Testing 365
10.10 Conclusion 365
References 366
11 Continuous Processing in the Pharmaceutical Industry: Status and Perspective 369Richard Steiner and Maik Jornitz
11.1 Industry Drivers for Continuous Processing: Competitive Advantages 369
11.2 Continuous Manufacturing in Bioprocessing 371
11.2.1 Continuous Bioprocessing Enablers and Guidance 371
11.2.2 Process Technologies 372
11.2.3 Examples of Continuous Manufacturing 376
11.2.4 Economic and Design Implications 377
11.3 Continuous Manufacturing for Oral Solid Dosage Forms 381
11.3.1 Industry Approaches to the Implementation of cm 381
11.3.2 Typical Installation Layouts 383
11.3.3 Economic Justification and Business Excellence 387
11.4 The Pharmaceutical Supply Chain of the Future 395
11.4.1 Portable, Continuous, Miniature and Modular 395
11.4.2 The PCMM Concept 396
11.4.3 Discussion 399
11.5 Conclusion 400
Acknowledgments 401
References 401
12 Design of an Integrated Continuous Manufacturing System 405Sarang S. Oka, M. Sebastian Escotet-Espinoza, Ravendra Singh, James V. Scicolone, Douglas B. Hausner, Marianthi Ierapetritou and Fernando J. Muzzio
12.1 Introduction 405
12.2 Step 1: Rough Conceptual Design 406
12.2.1 Type of Product 406
12.2.2 Type of Manufacturing Route - Direct Compaction, Wet Granulation or Dry Granulation 407
12.2.3 Flexible or Dedicated 408
12.2.4 Feeding Multiple Ingredients, Including Pre-blends 408
12.2.5 Strategy for Sensing and Control 409
12.2.6 Regulatory Strategy 409
12.3 Step 2: Material Property Screening 410
12.4 Step 3: Characterizing Unit Operation Using Actual Process Materials 412
12.4.1 Loss in Weight Feeders 412
12.4.2 Continuous Blenders 415
12.5 Step 4: Develop and Calibrate Unit Operation Models Including Process Materials 422
12.5.1 Application of the Model Development Algorithm in Pharmaceutical Problems 422
12.5.2 Recommendations for Developing a Unit Operation Model that Incorporates the Effects of Material Properties 423
12.6 Step 5: Develop an Integrated Model of an Open Loop System 424
12.6.1 Model Integration Basics 425
12.6.2 General Algorithm for Building an Integrated Model 425
12.7 Step 6: Examine Open Loop Performance of the Process 427
12.8 Step 7: Develop/Fine Tune PAT Methods for Appropriate Unit Operations 429
12.9 Step 8: Implement Open Loop Kit with PAT and IPCs Enabled 430
12.10 Step 9: Design of the Control Architecture 432
12.11 Step 10: Develop Integrated Model of Closed Loop System 436
12.12 Step 11: Implementation and Verification of the Control Framework 438
12.13 Step 12: Characterize and Verify Closed Performance 440
12.14 Conclusions 442
References 443
13 End to End Continuous Manufacturing: Integration of Unit Operations 447R. Lakerveld, P. L. Heider, K. D. Jensen, R. D. Braatz, K. F. Jensen, A. S. Myerson, and B. L. Trout
13.1 Introduction 447
13.2 Process Description 448
13.2.1 Specific Benefits Obtained as a Result of cm 452
13.3 System Dynamics 452
13.3.1 Model-based Design and Control are the Governing Concepts in cm 452
13.3.2 The Absence of True Steady-state Operation and the Implications for Product Quality Control 453
13.3.3 Plant-wide Control for CM: Disentanglement of Times Scales and Control Objectives 455
13.3.4 Residence Time Distribution of a CM Process: Impact of Recycling 456
13.3.5 Disturbances, Nonlinearities, and Delays: Implications for Control 460
13.3.6 Startup and Shutdown Procedures 464
13.3.7 Buffering 465
13.4 Process Monitoring and Control 468
13.4.1 PAT Use in the Integrated Continuous Manufacturing Process 468
13.4.2 Soft Sensors and Prediction of Future Performance 469
13.5 Outlook: Opportunities for Novel Unit Operations and System Configurations 471
13.6 Summary and Closing Thoughts 477
References 480
14 Methodology for Economic and Technical Comparison of Continuous and Batch Processes to Enhance Early Stage Decision-making 485Isabella Aigner, Wen-Kai Hsiao, Diana Dujmovic, Sven Stegemann and Johannes Khinast
14.1 Introduction 485
14.2 Technical-Economic Evaluation Methodology 486
14.2.1 Definition of the System Boundaries and Performance Targets 488
14.2.2 Modeling of the Process Chains 489
14.2.3 Performing Technical Feasibility and Risk Assessment 490
14.2.4 Evaluation of the Process Options 492
14.2.5 Calculation of Process Costs, Cost Comparison and Interpretation 498
14.2.6 Technology-Economic Profiling and Interpretation of Results 498
14.2.7 Performing Scenario, Sensitivity and Uncertainty Analysis 502
14.3 Conclusion 502
References 504
15 Drivers for a Change - Manufacturing of Future Medicines for Personalized Drug Therapies 507Jukka Rantanen and Jörg Breitkreutz
15.1 Introduction 507
15.2 Personalized Medicine 508
15.2.1 Therapy Based on Individualized Needs for Different Patient Groups 508
15.2.2 Point of Care Diagnostics 509
15.3 Flexible Dosing with Innovative Products 510
15.4 Future Health Care Scenario 513
15.4.1 Enabling Manufacturing Technologies and Materials Science 513
15.4.2 The Regulatory Environment 518
15.4.3 Supply Chain 520
References 521
16 Perspectives of Printing Technologies in Continuous Drug Manufacturing 525Niklas Sandler and Petri Ihalainen
16.1 Introduction 525
16.1.1 Printing Technologies - Enablers of Continuous Drug Manufacturing Approaches 525
16.2 Inkjet (Microdrop Generation Techniques) 527
16.2.1 Inkjet - Technical Description 527
16.2.2 Ink Development and Printability 531
16.2.3 Pharmaceutical Applications of Inkjet Printing 533
16.3 Flexographic Printing 535
16.3.1 Flexography - Technique Description 535
16.3.2 Pharmaceutical Applications of Flexographic Printing 537
16.4 Formulation Approaches for Inkjet and Flexography 538
16.5 Process Control and Process Analytical Technology for Continuous Printing Applications 539
16.6 From Laboratory-scale Printing Towards an Industrial Scale 540
16.7 Three-dimensional Printing/Additive Manufacturing 541
16.7.1 From Prototyping to Large-scale Manufacturing 542
16.7.2 Fused Deposition Modeling or Fused Filament Fabrication 543
16.7.3 Feedstock Material for FDM Printing 544
16.7.4 3D Printing Techniques used in the Biomedical and Pharmaceutical Area 545
References 546
17 Development of Liquid Dispensing Technology for the Manufacture of Low Dose Drug Products 551Allan Clarke and Dave Doughty
17.1 Introduction 551
17.2 Background 552
17.3 Goals for the LDT Program 554
17.4 Overview of LDT 555
17.4.1 Formulation Overview 555
17.4.2 LDT Platforms 557
17.5 LDT Machine Design Details 559
17.5.1 Commercial Line Operation 559
17.5.2 Liquid Dispensing Cell 560
17.5.3 Solvent Evaporation 563
17.5.4 Inspection Systems on the Commercial Machine for Critical Quality Attributes 563
17.5.5 Pad Printing Cell 565
17.6 Scale-independence of the LDT Technology 566
17.7 Real-time Release Potential 567
17.8 Occupational Health, Environmental and Cleaning Considerations 570
17.8.1 Occupational Health 570
17.8.2 Environmental Controls/Cleaning 572
17.9 Conclusion 573
Acknowledgments 574
References 574
Index 577
Johannes Khinast1,2 and Massimo Bresciani2
1Institute of Process and Particle Engineering, Graz University of Technology, Austria
2Research Center for Pharmaceutical Engineering, Graz, Austria
In chemical engineering, manufacturing processes can be categorized in different ways, one being the mode of operation with respect to the strategy of feeding and removing materials from a process unit. Specifically, one distinguishes between:
Thus, continuous manufacturing (CM) is a method of manufacturing products and processing materials without interruption and with constant material feed and removal. Also tableting, which actually is a batch operation on the scale of a single die, can be viewed as a continuous process. In contrast to batch manufacturing, in a continuous process materials remain constantly in motion, undergo chemical transformations, or are subject to mechanical or heat treatment. Continuous processing on a large scale generally means operating 24 h/day, 7 days/week (often called 24/7) with infrequent (weekly, monthly, semi-annual, or annual) planned maintenance shutdowns. However, continuous manufacturing can also be carried out on a campaign basis, that is, semi-continuous manufacturing of an intermediate chemical compound for a few weeks in a continuous plant.
The concept of continuous processing is not new. It has widely been used across the industry, including oil refining and the production of chemicals, fertilizers, paper, and foods. One of the earliest continuous processes relates to the paper industry (Fourdrinier paper machine, patented in 1799). Automotive manufacturing (at least the assembly part) can also be viewed as a continuous process. Here, the first assembly lines were installed at the beginning of the twentieth century by Olds (Oldsmobile) and, with more publicity, several years later by Ford (Ford model T).
Although not used on a broad basis, continuous manufacturing is not new to the pharmaceurical sector. Some pharmaceutical manufacturing processes (e.g., separations) have operated continuously for decades [1]. Furthermore, many pharmaceutical unit operations, such as plug-flow reactors, roller compaction, tablet compression, extrusion, and capsule filling, are inherently continuous process steps. Yet, since continuous quality assurance was not integrated in these processes in the past, they remain continuous processes operated in a batch way and will only become truly continuous when real-time quality assurance is fully implemented in the process control.The first publication by ICI, clearly outlining the advantages of continuous manufacturing (as they are cited today), dates back to 1984 [2].
On the academic side, continuous manufacturing of pharmaceuticals has been studied for more than two decades. In the early 1990s, Muzzio at Rutgers University launched the first research program for the continuous manufacturing of pharmaceuticals. In addition, Leuenberger (University of Basel) early on pointed out the advantages of continuous manufacturing in the pharmaceutical industry [3]. Since then, significant efforts have been made in this field, and several focused research programs are currently underway. For example, the Novartis-MIT center for continuous manufacturing (USA) focuses on primary active pharmaceutical ingredient (API) manufacturing and integrating drug synthesis into a continuous production line [4]. Continuous manufacturing and crystallisation (CMAC) at Strathclyde University (UK) investigates related topics that range from synthesis to crystallization. A series of white papers from the International Symposium on Continuous Manufacturing of Pharmaceuticals [5], organized jointly by MIT and CMAC, highlights the current view on CM. In the field of secondary manufacturing (drug product), together with its partners at Purdue University, NJIT, and University of Puerto Rico, Rutgers University developed a continuous manufacturing plant based on blending and direct compaction within their NSF-funded research center C-SOPS [6]. The Research Center for Pharmaceutical Engineering (RCPE) currently leads the European Consortium for Continuous Manufacturing, fearuring three continuous lines. Its partners are the groups of Ketolainen at University of Eastern Finland (roller-compaction based granulation), Remon and De Beer at Ghent University (wet granulation lines), Kleinebudde at Heinrich-Heine University (roller compaction), and Graz University of Technology (hot-melt extrusion and down-streaming).
Several system suppliers have developed GMP-certified continuous manufacturing lines. One approach to integrating multiple continuous unit operations into a continuous downstream line is the Consigma system by GEA. It is an integrated tableting line with continuous wet granulation via co-rotating twin-screw extrusion, semi-continuous drying in a segmented fluid bed and tableting with state of the art online monitoring systems [7]. Recently, GLATT introduced the "MODCOS" system, which is a continuous rotary chamber insert for converting Glatt's GPCG drying batch system into a continuous fluidized bed drying system. In combination with various associated continuous process equipment from other companies [e.g., feeders, process analytical technology (PAT), and continuous granulation systems] it makes an integrated continuous wet granulation line possible. Moreover, other advanced industrial systems are under development, such as the continuous manufacturing line(s) by Bohle for blending, dry and wet granulation, tableting, and coating. Bosch is another equipment company developing downstream continuous manufacturing systems in cooperation with RCPE. Continuus Pharmaceuticals, a spin-off from MIT is offering equipment for continuous synthesis and dosage-form manufacturing. Similarly, suppliers of continuous flow chemistry systems are increasingly active on the market (Thalesnano, Syrris, Ehrfeld, AM Technology, Uniqsis, Chemtrix, Future Chemistry, Vapourtec and others).
In addition, several pharmaceutical companies have started significant programs on continuous manufacturing, such as Novartis, Pfizer (recently in a joint effort with GEA), AstraZeneca, GSK, Bayer, UCB and many others. In fact, in 2015 the FDA approved a continuous manufacturing plant by Vertex in the USA (for Orkambi, a drug treating cystic fibrosis) and in 2016 a continuous line by Jannsen (for Darunavir, a drug for treating HIV infections) in Puerto Rico. At time of the writing of this book, also other approvals are in the pipeline, not only in the United States, but also in Europe and other regulatory regions.
Traditional batch manufacturing follows a sequential approach. Before processing, the materials are introduced into a specific unit operation, then transformed into a processed intermediate product and finally discharged at the end of processing. After each production step the intermediate products are collected and analyzed, if required, and physically transported in various containers (IBCs) to the next process step. Typically, the intermediate and final products are extensively tested off-line in a quality assurance laboratory. Frequently, intermediates are shipped across the globe from one production site to the next one that has suitable equipment using cold-chain systems or freeze containers, which may lead to segregation or instability. Depending on the number and nature of the unit operations (typically 10-30), a batch manufacturing process on a commercial scale may last from several weeks to a year (or longer).
In contrast, it only takes a few hours or days to make the final product via a CM process that consists of the same unit operations as the batch process. Simultaneously introduced into and discharged from the process, the material is automatically transferred and monitored and controlled in-line along the manufacturing path. Based on the implemented control strategy, the process can be adjusted by means of in-process measurements. The quality is assured (QA) in real-time, and - in theory - real-time release is possible.
Figure 1.1 General overview of a CM process chain.
Pharmaceutical manufacturing is typically divided into primary and secondary. Primary manufacturing is the production of an API and excipient materials. Secondary manufacturing is the production of a final dosage form. In oral dosage form production, crystallization, filtration, washing, and drying steps are considered primary steps, and dry API is made at primary manufacturing plants. Lyophilization of proteins,...
Dateiformat: ePUBKopierschutz: Adobe-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet – also für „fließenden” Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein „harter” Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.Bitte beachten Sie: Wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!
Weitere Informationen finden Sie in unserer E-Book Hilfe.
